Bernstein V, et al. - Authors, in this multicentre, randomized, phase II trial, determined the efficacy and safety of adding pelareorep to paclitaxel for patients with metastatic breast cancer (mBC). Pelareorep addition to paclitaxel in previously treated mBC seemed to create no difference in progression-free survival (the primary endpoint) or RR. However, there was a significantly longer overall survival (OS) for the combination.